Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Name: Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis
Creator: Daniel S. Alicea, MS
Published: 2024-11-11T20:51:27.121Z
Keywords: Dermatology, Oncology

Alicea, MS, Daniel S.; Miao, PharmD, MD, Emily; Ch'en, BS, Peter; Tuckman, MBA, Steven W.; Ohri, MD, MS, Nitin; Halmos, MD, Balazs; Cheng, MD, PhD, Haiying; Lee, MD, MPH, Matthew; McLellan, MD, Beth N.

doi:10.17632/pnb8kwtfh2.1

Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Published: 11 November 2024| Version 1 | DOI: 10.17632/pnb8kwtfh2.1

Contributors:

Daniel S. Alicea, MS, Emily Miao, PharmD, MD, Peter Ch'en, BS, Steven W. Tuckman, MBA, Nitin Ohri, MD, MS, Balazs Halmos, MD, Haiying Cheng, MD, PhD, Matthew Lee, MD, MPH, Beth N. McLellan, MD

Description

An additional Kaplan-Meier curve seen in supplemental Figure 1 was conducted to assess overall survival among groups with and without the development of a cutaneous treatment related adverse event; results showed similar survival among the groups (p=0.960).

Files

Steps to reproduce

Kaplan-Meier curves were generated for overall survival and log-rank test compared the curves between patients with and without the development of a cutaneous TRAE.

Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Description

Files

Steps to reproduce

Categories

Licence